$8.60
0.05[0.58%]
Last update: 7:09PM Get Real Time Here
AVITA Medical
(NASDAQ:RCEL)AVITA Medical Stock (NASDAQ:RCEL), Analyst Ratings, Price Targets, Predictions
AVITA Medical Inc has a consensus price target of $22.6, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from BTIG, Piper Sandler, and Cantor Fitzgerald on April 11, 2024, February 23, 2024, and February 23, 2024. With an average price target of $15.33 between BTIG, Piper Sandler, and Cantor Fitzgerald, there's an implied 67.94% upside for AVITA Medical Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
Piper Sandler
Cantor Fitzgerald
B of A Securities
Lake Street
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for AVITA Medical
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | RCEL | Buy Now | AVITA Medical | $9.13 | — | BTIG | Ryan Zimmerman | — | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2024 | RCEL | Buy Now | AVITA Medical | $9.13 | 130.01% | Piper Sandler | Matt O'Brien | $19 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | RCEL | Buy Now | AVITA Medical | $9.13 | 173.82% | Cantor Fitzgerald | Ross Osborn | $22 → $25 | Maintains | Overweight | Get Alert |
| 01/19/2024 | RCEL | Buy Now | AVITA Medical | $9.13 | 140.96% | Cantor Fitzgerald | Ross Osborn | $20 → $22 | Maintains | Overweight | Get Alert |
| 11/21/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 119.06% | Cantor Fitzgerald | Ross Osborn | → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 11/10/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 108.11% | Piper Sandler | Matt O'Brien | $23 → $19 | Maintains | Overweight | Get Alert |
| 10/19/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 184.78% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 184.78% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 184.78% | Cantor Fitzgerald | Ross Osborn | → $26 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 151.92% | Piper Sandler | Matt O'Brien | $18.5 → $23 | Maintains | Overweight | Get Alert |
| 07/28/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 195.73% | B of A Securities | Lyanne Harrison | $18 → $27 | Maintains | Buy | Get Alert |
| 07/13/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 338.12% | Lake Street | Brooks O'Neil | $30 → $40 | Maintains | Buy | Get Alert |
| 06/27/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 151.92% | Cantor Fitzgerald | Ross Osborn | → $23 | Initiates | → Overweight | Get Alert |
| 06/26/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 228.59% | Lake Street | Brooks O'Neil | → $30 | Maintains | Buy | Get Alert |
| 06/09/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 228.59% | Lake Street | Brooks O'Neil | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 228.59% | Lake Street | Brooks O'Neil | $30 → $30 | Maintains | Buy | Get Alert |
| 05/12/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 102.63% | Piper Sandler | Matt O'Brien | $16 → $18.5 | Maintains | Overweight | Get Alert |
| 04/17/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 108.11% | BTIG | Ryan Zimmerman | $16 → $19 | Maintains | Buy | Get Alert |
| 02/24/2023 | RCEL | Buy Now | AVITA Medical | $9.13 | 228.59% | Lake Street | Brooks O'Neil | → $30 | Maintains | Buy | Get Alert |
FAQ
What is the target price for AVITA Medical (RCEL)?
The latest price target for AVITA Medical (NASDAQ: RCEL) was reported by BTIG on April 11, 2024. The analyst firm set a price target for $0.00 expecting RCEL to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AVITA Medical (RCEL)?
The latest analyst rating for AVITA Medical (NASDAQ: RCEL) was provided by BTIG, and AVITA Medical downgraded their neutral rating.
When was the last upgrade for AVITA Medical (RCEL)?
There is no last upgrade for AVITA Medical.
When was the last downgrade for AVITA Medical (RCEL)?
The last downgrade for AVITA Medical Inc happened on April 11, 2024 when BTIG changed their price target from N/A to N/A for AVITA Medical Inc.
When is the next analyst rating going to be posted or updated for AVITA Medical (RCEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating AVITA Medical (RCEL) correct?
While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price AVITA Medical (RCEL) is trading at is $8.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.